Answer
Defibrotide is contraindicated with recombinant t-PA because co-administration may increase haemorrhage risk, based on a mouse thromboembolism model in which intravenous recombinant t-PA potentiated defibrotide’s antithrombotic effect.
Sources for this answer
- Defitelio 80 mg/mL concentrate for solution for infusionJazz Pharmaceuticals UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 14Document updated
Sources checked